A clinical study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma

Trial Profile

A clinical study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs DKN 01 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2017 According to a Leap Therapeutics media release, the first patient has been dosed in this trial. Dr. Samuel Klempner, is an investigator on the study.
    • 13 Nov 2017 Status changed from planning to recruiting, according to a Leap Therapeutics media release.
    • 28 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top